182 related articles for article (PubMed ID: 32878621)
1. Alteration of plasma metabolites associated with chemoradiosensitivity in esophageal squamous cell carcinoma via untargeted metabolomics approach.
Zhang Y; Wang J; Dai N; Han P; Li J; Zhao J; Yuan W; Zhou J; Zhou F
BMC Cancer; 2020 Sep; 20(1):835. PubMed ID: 32878621
[TBL] [Abstract][Full Text] [Related]
2. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach.
Fujigaki S; Nishiumi S; Kobayashi T; Suzuki M; Iemoto T; Kojima T; Ito Y; Daiko H; Kato K; Shouji H; Honda K; Azuma T; Yoshida M
Biomark Med; 2018 Aug; 12(8):827-840. PubMed ID: 30043633
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
4. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
5. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Wang WT; Guo CQ; Cui GH; Zhao S
World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics-based Discovery of Serum Biomarkers to Predict the Side-effects of Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.
Nishiumi S; Fujigaki S; Kobayashi T; Kojima T; Ito Y; Daiko H; Kato K; Shoji H; Kodama Y; Honda K; Yoshida M
Anticancer Res; 2019 Jan; 39(1):519-526. PubMed ID: 30591504
[TBL] [Abstract][Full Text] [Related]
7. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers.
Xu J; Chen Y; Zhang R; Song Y; Cao J; Bi N; Wang J; He J; Bai J; Dong L; Wang L; Zhan Q; Abliz Z
Mol Cell Proteomics; 2013 May; 12(5):1306-18. PubMed ID: 23397110
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
10. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M
World J Surg; 2014 Aug; 38(8):2046-51. PubMed ID: 24615604
[TBL] [Abstract][Full Text] [Related]
12. Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform.
Liu R; Peng Y; Li X; Wang Y; Pan E; Guo W; Pu Y; Yin L
Int J Mol Sci; 2013 Apr; 14(5):8899-911. PubMed ID: 23615477
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
14. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
15. Serum Cytokines Correlate with Pretreatment Body Mass Index-adjusted Body Weight Loss Grading and Cancer Progression in Patients with Stage III Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy Followed by Surgery.
Pan YP; Kuo HC; Lin JY; Chou WC; Chang PH; Ling HH; Yeh KY
Nutr Cancer; 2024; 76(6):486-498. PubMed ID: 38680010
[TBL] [Abstract][Full Text] [Related]
16. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
[TBL] [Abstract][Full Text] [Related]
17. Serum metabolomic signatures of lymph node metastasis of esophageal squamous cell carcinoma.
Jin H; Qiao F; Chen L; Lu C; Xu L; Gao X
J Proteome Res; 2014 Sep; 13(9):4091-103. PubMed ID: 25162382
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
19. ZNF750 Expression as a Novel Candidate Biomarker of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma.
Otsuka R; Akutsu Y; Sakata H; Hanari N; Murakami K; Kano M; Takahashi M; Matsumoto Y; Sekino N; Yokoyama M; Iida K; Matsubara H
Oncology; 2017; 93(3):197-203. PubMed ID: 28558382
[TBL] [Abstract][Full Text] [Related]
20. Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy.
Zhou XL; Zhu WG; Zhu ZJ; Wang WW; Deng X; Tao WJ; Ji FZ; Tong YS
Oncologist; 2019 Aug; 24(8):e677-e686. PubMed ID: 31040254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
